Ep. 106 - China's C-suite Hears FDA, Plus AACR, ARPA-H
BioCentury This Week
00:00
I Think It's a Practical Matter, Steve.
i think, i think ia's a practical matter. It's ben extraordinarily difficult for any one, any company, to test a pty one against tohead against a marketed pt one. If the new pety ones are going to be in these kind of niche indications where there's no other pety one approve, then there'll be no reason for them to price them below the levels of other pety ones. A couple of respondents saidthat they were thinking about different ndiaton. Swe don't know who responded. What i do suspect that some of them may have had earlier phase programmes. But you've got a bunch of companies, they say they're doing global trials
Transcript
Play full episode
